Accera, Inc. to Present at the BioPharm America™ 2012 Partnering Conference in Boston, MA
BROOMFIELD, Colo., Sept. 13, 2012 /PRNewswire/ -- Accera, Inc., a privately-held, commercial-stage, healthcare company focused on the discovery and development of innovative clinical applications to address acute and chronic neurodegenerative diseases, announced today that Holger Kunze, president and CEO of Accera, will be presenting at the BioPharm America 2012 Partnering Conference on September 20, 2012 at 2:30 p.m. ET in the Otis Room at the Westin Boston Waterfront Hotel in Boston, MA. The presentation will provide an overview of the company, its marketed product, Axona®, and will highlight Accera's recent partnership with Nestle Health Science, expanded commercial efforts and clinical development plans.
"We are delighted to have the opportunity to present at this year's BioPharm America conference," said Mr. Kunze. "Given our recent partnership with Nestle Health Science, expanded commercialization efforts and clinical development, we're eager to showcase Accera's recent milestones and plans for the future."
Accera's marketed product, Axona, is a specially formulated, prescription-only medical food intended for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's disease (AD). It is the first proprietary commercialized AD product that addresses the well-recognized physiological hallmark of the brain's inability to optimally metabolize glucose (hypometabolism) by providing an alternative energy source for brain cells.
About Accera, Inc.
Accera, Inc. is a privately held commercial-stage healthcare company that developed and now markets Axona in the US. Accera is engaged in the research, development and commercialization of other clinical applications for Axona and AC-1204 in acute and chronic neurodegenerative diseases. For more information about Accera, please visit www.accerapharma.com.
About Axona®
Axona is a prescription-only medical food intended for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's disease. For more information about Axona, please visit www.about-axona.com or ask your physician.
Accera, Inc. | Tiberend Strategic Advisors, Inc.
|
SOURCE Accera, Inc.